#企业/市场
#企业/市场
今日 3 条
Editas Medicine@editasmedAI 评分88
Moderna@moderna_txAI 评分1818
Pfizer Inc.@pfizerAI 评分88
Moderna@moderna_txAI 评分2020
Ionis@ionispharma精选AI 评分5757Ionis 宣布与 Recordati 签署授权协议,授予后者在美国以外所有国家开发及商业化其针对亚历山大病的在研 RNA 靶向药物的独家权利。该药物目前仍处于在研阶段,交易具体金额未在文中披露。
推荐理由:Ionis 将一款在研 RNA 靶向药物的美国以外权益授权给 Recordati,读者可了解该罕见病管线的地域权益划分。
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分88
AstraZeneca@AstraZenecaAI 评分88
Biogen@biogenAI 评分88本周我们在圣地亚哥参加#BIO2026,期待与来自全球的生物技术领袖交流,他们与我们一样,怀揣着为患者带来改变生命的药物的雄心。了解我们在全球的合作机会:https://bit.ly/4gudEJC

Sanofi@sanofiAI 评分2222
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分1010
Sanofi@sanofiAI 评分88
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分88
Biogen@biogenAI 评分4242
Amgen 🧪🔬🧬@AmgenAI 评分88生物类似药的下一步是什么?在安进,持续的开发和制造专长正在帮助推动未来。观看了解更多:https://amgen.ly/4eg6DdX

Johnson & Johnson@JNJNewsAI 评分2222
Gilead Sciences@GileadSciencesAI 评分1212
Bristol Myers Squibb@bmsnewsAI 评分33在全球迎接 2026 #FIFAWorldCup 之际,我们为患者而战的努力从未停歇。了解为什么 #BMSWontLose,请访问 http://bmswontlose.com

Legend Biotech@LegendBiotechAI 评分55
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分88
Bristol Myers Squibb@bmsnewsAI 评分33
Incyte@Incyte精选AI 评分5252
推荐理由:Incyte 通过收购 Star biotech 旗下 Vega Therapeutics 切入出血性疾病领域,可观察其血液学管线的外延方向。
Ionis@ionispharmaAI 评分1212
Bristol Myers Squibb@bmsnewsAI 评分88
AstraZeneca@AstraZenecaAI 评分2020
Regeneron@RegeneronAI 评分33
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分1010
Editas Medicine@editasmedAI 评分4242
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分88
Editas Medicine@editasmedAI 评分22
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分22
Incyte@IncyteAI 评分2222Incyte 与 @genesismolai 正在扩大我们的合作,旨在加速潜在新药的发现。了解更多。https://bit.ly/4uiY5sl

Incyte@IncyteAI 评分3535引用Sam Rodriques@SGRodriquesWe live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we.